Drug intelligence / Profile preview

rituximab + ifosfamide + carboplatin

Development stage: Unknown
Lead developer: IDEC
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A combination chemotherapy regimen consisting of rituximab (a monoclonal antibody targeting CD20 on B cells), ifosfamide (an alkylating agent), and carboplatin (a platinum-based chemotherapy drug). This regimen is primarily used for treating relapsed or refractory B-cell non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia (B-ALL). The combination works through multiple mechanisms: rituximab targets CD20 on B cells, marking them for destruction by the immune system, while ifosfamide and carboplatin destroy rapidly dividing cells through DNA damage.

Other names: R-ICR-ICE (when including etoposide)RICE (when including etoposide)

Targets

CD20 (B-lymphocyte antigen CD20)DNA

Beyond the preview

Go deeper on rituximab + ifosfamide + carboplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rituximab + ifosfamide + carboplatin.

Explore the full profile